News Articles Tagged: SN38

Innovations in Oncology: NINGBO INNO PHARMCHEM CO.,LTD.'s Work on SN38-Glucose Conjugates

NINGBO INNO PHARMCHEM CO.,LTD. is at the cutting edge of oncology research, developing SN38-glucose conjugates to enhance targeted cancer therapy and improve patient outcomes.

NINGBO INNO PHARMCHEM CO.,LTD.: Leading the Way in Targeted Colorectal Cancer Therapies with SN38-Glucose Conjugates

NINGBO INNO PHARMCHEM CO.,LTD. is innovating targeted colorectal cancer therapies with SN38-glucose conjugates, enhancing drug delivery and efficacy by targeting cancer cell metabolism.

The Science Behind SN38-Glucose Conjugates: A Breakthrough by NINGBO INNO PHARMCHEM CO.,LTD. for Cancer Treatment

Understand the scientific principles behind NINGBO INNO PHARMCHEM CO.,LTD.'s SN38-glucose conjugates, a novel approach to cancer therapy that targets glucose uptake in cancer cells.

Exploring the Potential of Glucose Conjugates in Targeted Cancer Therapy by NINGBO INNO PHARMCHEM CO.,LTD.

Learn how NINGBO INNO PHARMCHEM CO.,LTD. is advancing cancer treatment with innovative SN38-glucose conjugates, targeting cancer cells via glucose transporters for enhanced efficacy and reduced side effects.